ArticleInternational ophthalmology2025
Evaluation of corneal epithelial thickness by anterior segment optical coherence tomography in glaucoma patients receiving topical prostaglandin and dry eye treatment.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory Pilot Study on the Tolerability and Ocular Surface Effects of Liposomal Ozonated Oil Compared with Standard Prophylaxis in Cataract Surgery. The CAREST Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate corneal epithelial thickness (CET) and tear break-up time (TBUT) in glaucoma patients receiving prostaglandin monotherapy and concurrent dry eye treatment, grouped according to the benzalkonium chloride (BAK) concentration levels of their eye drops, and to compare pre- and post-treatment measurements.
methodsEighty-two glaucoma patients with dry eye development while receiving prostaglandin monotherapy were included in this study. Patients were divided into three groups based on BAK exposure: Group 1 used two BAK-containing drops, Group 2 used one BAK-containing and one BAK-free drop, and Group 3 used only BAK-free drops. CET was measured by anterior segment optical coherence tomography (AS-OCT) within a 6-mm corneal diameter divided into 17 sectors. Comprehensive ophthalmic examinations and TBUT measurements were performed at each visit.
resultsNo significant differences were found among the groups in terms of age, sex, follow-up time, or intraocular pressure (p > 0.05). In Group 1, significant epithelial thinning was observed in the central 2 mm, paracentral 2-5 mm superior and nasal sectors, and mid-peripheral 5-6 mm nasal and inferior sectors (p < 0.05). In Groups 2 and 3, minimal changes were not significant (p > 0.05). TBUT differed significantly between groups at both visits (p < 0.001) and showed a weak positive correlation with CET changes (r = 0.291, p < 0.05).
conclusionSignificant corneal epithelial thinning was found only in patients using two BAK-containing drops. Despite receiving dry eye treatment, TBUT remained below normal in this group, possibly due to BAK's toxic effects on the tear film and epithelial cells. Monitoring CET by AS-OCT may help detect early signs of dry eye in clinical practice.
Indexed as
Identifiers
41240260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.